RENSSELAER, N.Y. (NEWS10) — Regeneron, whose Industrial Operations and Product Supply headquarters is in Rensselaer, and Sanofi announced the start of an international clinical trial for patients with severe COVID-19 on Monday.
This follows an announcement earlier this month of the start of the first trial, which was based in the U.S.
The multinational pharmaceutical companies say that the first patients in Italy, Spain, Germany, France, Canada, and Russia began treatment in clinical trials for Kevzara.
Kevzara blocks the receptor for a special kind of protein called interleukin-6, which could play a role in immune responses causing respiratory distress among coronavirus patients.
The international trial examines the safety and effectiveness of intravenous Kevzara, and will recruit about 300 hospitalized corona patients.
A preliminary study from China using a different IL-6 antibody gestures at the protein’s potential role in the pathology of coronavirus. In that study, which was not peer-reviewed, about 20 COVID-19 patients had lower fevers and needed less oxygen support.